Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Friedrich Hahn

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Plos One|April 8, 2017
Proteolysis of mature HIV-1 p6 Gag protein by the insulin-degrading enzyme (IDE) regulates virus replication in an Env-dependent mannerFriedrich Hahn, Adrian Schmalen, Christian Setz, et al.
Retrovirology|February 18, 2011
Highly conserved serine residue 40 in HIV-1 p6 regulates capsid processing and virus core assemblyJörg Votteler, Liane Neumann, Sabine Hahn, et al.
Antiviral Research|October 1, 2018
Novel cytomegalovirus-inhibitory compounds of the class pyrrolopyridines show a complex pattern of target binding that suggests an unusual mechanism of antiviral activityFriedrich Hahn, Corina Hutterer, Christophe Henry, et al.
International Journal of Molecular Sciences|January 12, 2021
Combinatorial Drug Treatments Reveal Promising Anticytomegaloviral Profiles for Clinically Relevant Pharmaceutical Kinase Inhibitors (PKIs)Markus Wild, Jintawee Kicuntod, Lisa Seyler, et al.
International Journal of Molecular Sciences|December 10, 2021
Development of a PROTAC-Based Targeting Strategy Provides a Mechanistically Unique Mode of Anti-Cytomegalovirus ActivityFriedrich Hahn, Stuart T Hamilton, Christina Wangen, et al.
Antiviral Research|November 20, 2018
In vivo proof-of-concept for two experimental antiviral drugs, both directed to cellular targets, using a murine cytomegalovirus modelEric Sonntag, Friedrich Hahn, Luca D Bertzbach, et al.
Pharmaceutics|February 24, 2024
An Antiherpesviral Host-Directed Strategy Based on CDK7 Covalently Binding Drugs: Target-Selective, Picomolar-Dose, Cross-Virus ReactivityDongHoon Yu, Sabrina Wagner, Martin Schütz, et al.
Viruses|December 9, 2020
IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In VitroFriedrich Hahn, Christina Wangen, Sigrun Häge, et al.
Oncotarget|June 21, 2019
Flow based single cell analysis of the immune landscape distinguishes Barrett's esophagus from adjacent normal tissueMoen Sen, Friedrich Hahn, Taylor A Black, et al.
Oncotarget|September 7, 2019
Correction: Flow based single cell analysis of the immune landscape distinguishes Barrett's esophagus from adjacent normal tissueMoen Sen, Friedrich Hahn, Taylor A Black, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Plos One|April 8, 2017
Proteolysis of mature HIV-1 p6 Gag protein by the insulin-degrading enzyme (IDE) regulates virus replication in an Env-dependent mannerFriedrich Hahn, Adrian Schmalen, Christian Setz, et al.
Retrovirology|February 18, 2011
Highly conserved serine residue 40 in HIV-1 p6 regulates capsid processing and virus core assemblyJörg Votteler, Liane Neumann, Sabine Hahn, et al.
Antiviral Research|October 1, 2018
Novel cytomegalovirus-inhibitory compounds of the class pyrrolopyridines show a complex pattern of target binding that suggests an unusual mechanism of antiviral activityFriedrich Hahn, Corina Hutterer, Christophe Henry, et al.
International Journal of Molecular Sciences|January 12, 2021
Combinatorial Drug Treatments Reveal Promising Anticytomegaloviral Profiles for Clinically Relevant Pharmaceutical Kinase Inhibitors (PKIs)Markus Wild, Jintawee Kicuntod, Lisa Seyler, et al.
International Journal of Molecular Sciences|December 10, 2021
Development of a PROTAC-Based Targeting Strategy Provides a Mechanistically Unique Mode of Anti-Cytomegalovirus ActivityFriedrich Hahn, Stuart T Hamilton, Christina Wangen, et al.
Antiviral Research|November 20, 2018
In vivo proof-of-concept for two experimental antiviral drugs, both directed to cellular targets, using a murine cytomegalovirus modelEric Sonntag, Friedrich Hahn, Luca D Bertzbach, et al.
Pharmaceutics|February 24, 2024
An Antiherpesviral Host-Directed Strategy Based on CDK7 Covalently Binding Drugs: Target-Selective, Picomolar-Dose, Cross-Virus ReactivityDongHoon Yu, Sabrina Wagner, Martin Schütz, et al.
Viruses|December 9, 2020
IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In VitroFriedrich Hahn, Christina Wangen, Sigrun Häge, et al.
Oncotarget|June 21, 2019
Flow based single cell analysis of the immune landscape distinguishes Barrett's esophagus from adjacent normal tissueMoen Sen, Friedrich Hahn, Taylor A Black, et al.
Oncotarget|September 7, 2019
Correction: Flow based single cell analysis of the immune landscape distinguishes Barrett's esophagus from adjacent normal tissueMoen Sen, Friedrich Hahn, Taylor A Black, et al.
Pageof 6